Fig. 6: High expression of TMCC3 correlates with poor clinical outcome of breast cancer patients. | Oncogene

Fig. 6: High expression of TMCC3 correlates with poor clinical outcome of breast cancer patients.

From: Transmembrane and coiled-coil ___domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation

Fig. 6

a, b The mRNA levels of TMCC3 in tumor specimens of 202 patients with breast cancer were analyzed by qRT-PCR. Kaplan–Meier plots of relapse-free survival (RFS) and overall survival (OS) for patients in relation to TMCC3 mRNA levels, and using Youden index to determine the optimal cutoff values defining high (red) and low (blue) expression groups. High and low expression of TMCC3 in relation to RSF (a) and OS (b) were shown in tumor tissue (n = 202) with breast cancer. High and low expression of TMCC3 in relation to RSF (c) and OS (d) were shown in stages 1–2 breast cancer tumor tissue (n = 161 for stages 1–2 breast cancers). In stages 1–2 luminal A + B breast cancers, high and low expression of TMCC3 in relation to RSF (e) and OS (f) were shown in tumor tissue (n = 120 for stages 1–2 luminal A + B breast cancers). Survival curves were plotted with Kaplan–Meier method, by the log-rank test applied for comparison. The Cox proportional-hazards regression model was employed to evaluate the independent prognostic factors. The statistical analyses were performed with Prism 5.0 (GraphPad Software, La Jolla) and SPSS ver. 22.0 (IBM, Armonk) software.

Back to article page